EHNA (erythro-9-(2-hydroxy-3-nonly)adenine) is a potent adenosine deaminase inhibitor,[1] which also acts as a phosphodiesterase inhibitor that selectively inhibits phosphodiesterase type 2 (PDE2).[2][3]

References

  1. ^ "Sigma Aldrich". Retrieved 16 January 2013.
  2. ^ Podzuweit T, Nennstiel P, Müller A (September 1995). "Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine". Cellular Signalling. 7 (7): 733–8. doi:10.1016/0898-6568(95)00042-N. PMID 8519602.
  3. ^ Méry PF, Pavoine C, Pecker F, Fischmeister R (July 1995). "Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes". Molecular Pharmacology. 48 (1): 121–30. PMID 7623766.


Allikas: https://en.wikipedia.org/wiki/EHNA
No tags for this post.